Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press29910.36691/RJA299ArticlesСтатьиResearch ArticleTHE ROLE OF MODERN ANTIHISTAMINES IN THE TREATMENT OF ALLERGIC DISEASESРОЛЬ СОВРЕМЕННЫХ АНТИГИСТАМИННЫХ ПРЕПАРАТОВ В ЛЕЧЕНИИ АЛЛЕРГИЧЕСКИХ ЗАБОЛЕВАНИЙNenashevaN MНенашеваНаталья Михайловна

профессор кафедры клинической аллергологии, доктор медицинских наук.

1444031@gmail.comRussian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России15102017144-5VOL 14, NO4-5 (2017)ТОМ 14, №4-5 (2017)808810032020Copyright ©; 2017, Pharmarus Print MediaCopyright ©; 2017, Фармарус Принт Медиа2017Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/299

Allergic rhinitis and urticaria - are common diseases which influence on the quality of life of patients reducing day activity and educability. The second generation of antihistamines are the first choice in the treatment of these diseases. At Russian pharmaceutical market a few dozens of different preparations of this group are available. Most of them are generic forms. The purpose of this article is to show the place of modern antihistamines in allergic rhinitis and urticaria therapy and to find out the best equivalent of generic antihistamine drug in comparison with the original one.

Аллергический ринит и крапивница - распространенные заболевания, существенно снижающие качество жизни больных и нарушающие трудоспособность и способность к обучению. Антигистаминные препараты II поколения являются средствами первого выбора в терапии этих заболеваний. На фармацевтическом рынке РФ доступно несколько десятков различных препаратов этой группы, большинство из которых являются генерическими формами. Настоящая статья посвящена месту современных антигистаминных препаратов в терапии АР и крапивницы, а также вопросу, какой генерический антигистаминный препарат можно считать эквивалентным оригинальному.

allergic rhinitisurticariasecond generation antihistamineslevocetirizinаллергический риниткрапивницаантигистаминные препараты II поколениялевоцетиризинBrozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, Brignardello-Petersen R, Canonica GW et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines - 2016 Revision, Journal of Allergy and Clinical Immunology (2017), doi: 10.1016/j.jaci.2017.03.050.GINA 2017 www.ginasthma.org.Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011;66:317-330.Zellweger F, Eggel A. IgE-associated allergic disorders: recent advances in etiology, diagnosis, and treatment. Allergy 2016;71:1652-1661.Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;3 Suppl 86:8-160.Papadopoulos NG, Bernstein JA, Demoly P, Dykewicz M, Fokkens W, Hellings PW et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy 2015;70:474-494.Ying S, Meng Q, Kay AB. The effect of levocetirizine on histamine and cytokine-induced upregulation of eotaxin by endothelial cells. Naples, France: Proceedings of the XXI Congress of the European Academy of Allergy and Clinical Immunology; 2001.Thomson L, Blaylock MG, Sexton DW, Campbell A, Walsh GM. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy. 2002;32:1187-1192.Wu P, Mitchell S, Walsh GM. A new antihistamine levocetirizine inhibits eosinophil adhesion to vascular cell adhesion molecule-1 under flow conditions. Clin Exp Allergy. 2005;35:1073-1079.Hasala H, Janka-Junttila M, Moilanen E, Kankaanranta H. Levocetirizine and cytokine production and apoptosis of human eosinophils. Allergy Asthma Proc. 2007;28:582-591.Инструкция по применению лекарственного препарата для медицинского применения Аллервэй.Corina I. Bocşan, Adriana I. Bujor, Nicolae Miron, Ştefan C. Vesa, Diana Deleanu, Anca D. Buzoianu. In vivo anti-inflammatory effect of H1-antihistamines in allergic rhinitis: A randomized clinical trial. Balkan Med J. 2015;32:352-8.Ralph Mosges, Volker Konig, Juliane Koberlein. The Effectiveness of ModernAntihistamines for Treatment of Allergic Rhinitis - An IPD Meta-Analysis of 140,853 Patients. Allergology International. 2013;62:215-222.Карева ЕН. Выбор антигистаминного препарата: взгляд фармаколога. РМЖ 2016;811816. [Kareva E.N. Vibor antigistaminnogo preparata: vzgljad pharmakologa. RMJ 2016;811816. (in Russ).].del Cuvillo A, Mullol J, Bartra J, Davila I, Jauregui I, Montoro J, Sastre J, Valero AL. Comparative pharmacology of the Hj-antihistamines. J Investig Allergol Clin Immunol. 2006;16, Supplement 1:3-12.Gillard M, Benedetti MS, Chatelain P et al. Inflamm. res. 2005;54: 367.Kornkiat Snidvongs, Kachorn Seresirikachorn, Likhit Khattiyawittayakun, Wirach Chitsuthipakorn. Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. Drugs 2017, Published online:09 January 2017, doi: 10.1007/s40265-016-0682-0.Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004;114: 838-844. 10.1016/j.jaci.2004.05.070.Bousquet J, Demarteau N, Mullol J, XPERT study group, et al. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy. 2005;60:788-794. 10.1111/j.1398-9995.2005.00820.x.Lipworth BJ, White PS. Allergic inflammation in the unified airway: start with the nose. Thorax. 2000;55(10): 878-881.Pasquali M, Baiardini I, Rogkakou A et al. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy. 2006;36:1161-1167.Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK et al. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64:1417-1426.Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009;39:777-87.Федеральные клинические рекомендации РААКИ по диагностике и лечению крапивницы. Российский Аллергологический Журнал 2016;№1:3745.Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014; doi: 10.1111/all.12313.Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676-682.Nelly Frossard, Margherita Strolin-Benedetti, Ashok Purohit, and Gabrielle Pauli. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol. 2008;65(2):172-179.